Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Cognitive Impairment in Breast Cancer
NCT02970500Phase 2Terminated
- Sponsor
- CHU de Québec-Université Laval
- Start
- Oct 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer-related cognitive impairment (CRCI) comparing Methylphenidate Group with Placebo Group (2 arms). Primary endpoint: Change in cognitive impairment level at 24 months. Started Oct 2017; status: terminated.
02
Drugs
methylphenidate
03
Conditions
cancer-related cognitive impairment (CRCI)
Beyond the preview
Go deeper on NCT02970500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970500.